Key result
Plasma SM 32:2 and ether lipids linked to subclinical atherosclerosis in type 1 diabetes.
Why the study?
To explore plasma lipidomics profiles in patients with type 1 diabetes and their potential associations with subclinical atherosclerosis.
Are specific plasma lipidomic profiles associated with subclinical atherosclerosis in patients with type 1 diabetes?
Observational (n=107)
Are specific plasma lipidomic profiles associated with subclinical atherosclerosis in patients with type 1 diabetes?
Specific plasma antioxidant molecules, including sphingomyelin and phosphatidylcholine, are associated with subclinical atherosclerosis in patients with type 1 diabetes, highlighting potential targets for personalized cardiovascular prevention.
Answers are grounded in this paper and cite their sources.
May inform risk stratification in type 1 diabetes; leaves open causal roles and preventive implications pending prospective data.
Here, we report on our study of plasma lipidomics profiles of patients with type 1 diabetes (T1DM) and explore potential associations. One hundred and seven patients with T1DM were consecutively recruited. Ultrasound imaging of peripheral arteries was performed using a high image resolution B-mode ultrasound system. Untargeted lipidomics analysis was performed using UHPLC coupled to qTOF/MS. The associations were evaluated using machine learning algorithms. SM(32:2) and ether lipid species (PC(O-30:1)/PC(P-30:0)) were significantly and positively associated with subclinical atherosclerosis (SA). This association was further confirmed in patients with overweight/obesity (specifically with SM(40:2)). A negative association between SA and lysophosphatidylcholine species was found among lean subjects. Phosphatidylcholines (PC(40:6) and PC(36:6)) and cholesterol esters (ChoE(20:5)) were associated positively with intima-media thickness both in subjects with and without overweight/obesity. In summary, the plasma antioxidant molecules SM and PC differed according to the presence of SA and/or overweight status in patients with T1DM. This is the first study showing the associations in T1DM, and the findings may be useful in the targeting of a personalized approach aimed at preventing cardiovascular disease in these patients.
No takes yet. Share an insight, caveat, or question.
Sojo et al. (2023) conducted an observational in Type 1 diabetes (T1DM) (n=107). Plasma lipidomics profiles was evaluated on Subclinical atherosclerosis and intima-media thickness. Plasma lipidomics profiles, specifically SM(32:2) and ether lipid species, were significantly and positively associated with subclinical atherosclerosis in patients with type 1 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: